KRAS and prostate carcinoma: Conversely, Black patients had a lesser risk of TP53 mutations in prostate cancer, KRAS mutations in pancreatic and endometrial cancers, and PIK3CA mutations in breast and endometrial cancers (Fig. 3B, D, and E).